Catalyst Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Catalyst Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E.
CEORichard John Daly
CEORichard John Daly
Employees181
Employees181
HeadquartersCoral Gables, Florida
HeadquartersCoral Gables, Florida
Founded2002
Founded2002
Employees181
Employees181
CPRX Key Statistics
Market cap2.96B
Market cap2.96B
Price-Earnings ratio14.07
Price-Earnings ratio14.07
Dividend yield—
Dividend yield—
Average volume1.19M
Average volume1.19M
High today$24.85
High today$24.85
Low today$23.73
Low today$23.73
Open price$24.00
Open price$24.00
Volume1.28M
Volume1.28M
52 Week high$26.58
52 Week high$26.58
52 Week low$19.05
52 Week low$19.05
Stock Snapshot
Catalyst Pharmaceuticals(CPRX) stock is priced at $24.00, giving the company a market capitalization of 2.96B. It carries a P/E multiple of 14.07.
On 2026-02-24, Catalyst Pharmaceuticals(CPRX) stock traded between a low of $23.73 and a high of $24.85. Shares are currently priced at $24.00, which is +1.1% above the low and -3.4% below the high.
Catalyst Pharmaceuticals(CPRX) shares are trading with a volume of 1.28M, against a daily average of 1.19M.
In the last year, Catalyst Pharmaceuticals(CPRX) shares hit a 52-week high of $26.58 and a 52-week low of $19.05.
In the last year, Catalyst Pharmaceuticals(CPRX) shares hit a 52-week high of $26.58 and a 52-week low of $19.05.
Analyst ratings
100%
of 7 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own CPRX. This list is generated using Robinhood data, and it’s not a recommendation.